Noninvasive imaging techniques may be helpful for identifying and monitoring eye problems in familial amyloid polyneuropathy (FAP), a study shows. Titled “Multimodal retinal…
News
Genetic sequencing can help to diagnose familial amyloid polyneruopathy (FAP) in people diagnosed with neuropathy of unknown origin — and sequencing is more reliable…
Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar,…
Urinary and sexual problems are highly prevalent in people with familial amyloid polyneuropathy (FAP) and should be tackled by a comprehensive and multidisciplinary…
Akcea Therapeutics’ next-generation antisense medicine AKCEA-TTR-LRx (ION-682884) — currently in development for the treatment of all forms…
Alexion Pharmaceuticals has obtained exclusive rights in Japan to develop and market AG10, an oral treatment candidate for familial amyloid polyneuropathy (FAP), also called…
Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest. …
Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive…
Lower Cathepsin E Levels Could Underlie Impaired Function of Macrophages in FAP, Study Suggests
The lower levels of a protein called cathepsin E, upon activation of a type of white blood cells called macrophages, in mice with familial…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of…
Recent Posts
- Being a caregiver means becoming an expert on your loved one’s disease
- Eye dryness, floaters common in hATTR-PN, but more research needed
- Approval of Beyonttra in Brazil brings new treatment options for ATTR-CM
- Real-world Amvuttra safety signals mostly match known profile
- FDA puts ATTR-CM therapy candidate coramitug on fast track